Metabolic diseases have become a global health concern, with a rising prevalence and limited treatment options. To address challenges, metabolic disease CROs rely on preclinical studies to evaluate the efficacy and safety of potential drug candidates. This service feature outlines a nonclinical animal experimental plan, including an estimated timeline, study budget, animal model selection, surgical procedures, in-life assessments, metabolic assessments, drug delivery system testing, and other important details necessary for the discovery and development of pharmaceutical drugs of endocrine-related diseases.
Animal Model Selection and Numbers for Statistical Significance
Selecting an appropriate animal model is crucial to translate to metabolic disease in humans. Commonly used animal models for metabolic diseases include rodents (mice and rats), non-human primates, and genetically modified animals. Each model has its advantages and limitations, and the selection will be based on the specific disease being studied. At Anilocus, we provide a wide variety of preclinical metabolic disease models that are customizable to your specific needs.
To ensure statistical significance, it is important to use an adequate number of animals per group. Sample size calculations, considering power analysis and effect size, should be conducted to determine the number of animals required to detect meaningful differences between treatment groups.
Study Timeline and Estimated Budget
The timeline for a nonclinical animal experimental plan can vary depending on the complexity of the study the specific sampling timepoints and the desired endpoints. Generally, it can range from several weeks to several months.
The estimated budget for preclinical metabolic disease research can also vary depending on the scale and scope of the study. The budget can range from a low-end estimate of $50,000 to a high-end estimate of $500,000 or more. When you’re determining your research budget consider factors such as animal procurement, animal husbandry, experimental procedures, and data analysis.
Surgical Procedures at Metabolic Disease CROs
Some metabolic disease studies may require surgical procedures to induce the disease phenotype or to implant devices for drug delivery or monitoring purposes. Surgical interventions should be performed by trained professionals following ethical guidelines and animal welfare standards.
Examples of surgical procedures include the induction of obesity through high-fat diet feeding, bariatric surgeries, or transplantation of pancreatic islet cells for diabetes research. These procedures should be carefully planned and executed to minimize any potential distress to the animals.
In-Life Assessments for Metabolic Endocrine Disorders
In-life assessments are critical to monitor the progression of metabolic diseases and evaluate the efficacy of potential drug candidates. These assessments typically involve regular measurements of body weight, food and water intake, glucose and lipid levels, blood pressure, and other relevant physiological parameters.
In addition, behavioral assessments, such as open field tests or maze tests, can provide valuable insights into the impact of metabolic diseases on cognition and mental health. These assessments would be conducted using validated protocols and equipment.
Metabolic Assessments
Metabolic assessments play a vital role in understanding the underlying mechanisms of endocrine-related diseases and evaluating the effects of potential therapeutic interventions. These assessments can include glucose tolerance tests, insulin sensitivity tests, lipid profiling, and metabolic imaging techniques such as Bruker Minispec Whole Body Composition NMR Analyzer of muscle, fat, and fluid in live animals.
Furthermore, the measurement of metabolic disease biomarkers, such as adipokines, cytokines, and inflammatory markers, can provide invaluable information about disease progression and treatment response. These assessments should be conducted using state-of-the-art technologies and validated methodologies.
Drug Delivery System Testing
To ensure the efficacy and safety of potential drug candidates, it is crucial to evaluate the drug delivery system. This includes assessing the pharmacokinetics and pharmacodynamics of the drug, determining the optimal dose and route of administration, and evaluating the drug’s stability in various physiological conditions.
Different drug delivery systems, such as oral formulations, injections, implants, or inhalation devices, may be tested depending on the specific drug and disease being studied. These tests should be conducted using appropriate controls and validated with analytical methods.
Anilocus Metabolic CRO Services Empower Pharmaceutical Drug Developers
Preclinical metabolic disease research plays a pivotal role in the discovery and development of pharmaceutical drugs. This comprehensive nonclinical metabolic CRO guide outlines the key aspects necessary for conducting effective and insightful studies for the development of novel therapeutics for metabolic endocrine disorders.
By carefully selecting appropriate animal models, conducting surgical procedures, performing in-life metabolic assessments, and evaluating drug delivery systems, pharmaceutical industry scientists can advance our understanding of metabolic diseases and develop effective treatment options for the most important people in the world: patients.
References
- Carias KV, Wevrick R. Preclinical Testing in Translational Animal Models of Prader-Willi Syndrome: Overview and Gap Analysis. Mol Ther Methods Clin Dev. 2019;13:344-358. Published 2019 Mar 14. doi:10.1016/j.omtm.2019.03.001.
- Seifirad S, Haghpanah V. Inappropriate modeling of chronic and complex disorders: How to reconsider the approach in the context of predictive, preventive and personalized medicine, and translational medicine. EPMA J. 2019;10(3):195-209. Published 2019 Jul 31. doi:10.1007/s13167-019-00176-z.
- “Disease Models, Animal”[MeSH]Martín-Carro B, Donate-Correa J, Fernández-Villabrille S, et al. Experimental Models to Study Diabetes Mellitus and Its Complications: Limitations and New Opportunities. Int J Mol Sci. 2023;24(12):10309. Published 2023 Jun 18. doi:10.3390/ijms241210309.
- Morishita Y, Arvan P. Lessons from animal models of endocrine disorders caused by defects of protein folding in the secretory pathway. Mol Cell Endocrinol. 2020;499:110613. doi:10.1016/j.mce.2019.110613.